English
简体中文
Total: £ 56.28
Published Date: 2025-08-08 | Pages: 80 | Tables: 80 | New Technology
The global siRNA Drugs market size was US$ 2443 million in 2024 and is forecast to a readjusted size of US$ 16238 million by 2031 with a CAGR of 28.9% during the forecast period 2025-2031.
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
"The 14th Five-Year Plan for the Development of the Pharmaceutical Industry": Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide "one-stop" services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the "patent pool" model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
The global siRNA Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Alnylam
Novartis
Novo Nordisk
Genzyme
Arrowhead
Silence
Sylentis
Avidity Biosciences
Sirnaomics
By Type: (Dominant Segment vs High-Margin Innovation)
Intravenous Injection
Subcutaneous Injection
By Application: (Core Demand Driver vs Emerging Opportunity)
Nervous System Therapy
Endocrine and Metabolic Therapy
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Alnylam in Europe)
- Emerging Product Trends: Intravenous Injection adoption vs. Subcutaneous Injection premiumization
- Demand-Side Dynamics: Nervous System Therapy growth in China vs. Endocrine and Metabolic Therapy potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of siRNA Drugs market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Subcutaneous Injection in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Endocrine and Metabolic Therapy in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the siRNA Drugs value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Intravenous Injection
1.2.3 Subcutaneous Injection
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Nervous System Therapy
1.3.3 Endocrine and Metabolic Therapy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global siRNA Drugs Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global siRNA Drugs Revenue Market Share by Region (2020-2025)
2.4 Global siRNA Drugs Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America siRNA Drugs Market Size and Prospective (2020-2031)
2.5.2 Europe siRNA Drugs Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific siRNA Drugs Market Size and Prospective (2020-2031)
2.5.4 Latin America siRNA Drugs Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa siRNA Drugs Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global siRNA Drugs Historic Market Size by Type (2020-2025)
3.2 Global siRNA Drugs Forecasted Market Size by Type (2026-2031)
3.3 Different Types siRNA Drugs Representative Players
4 Breakdown Data by Application
4.1 Global siRNA Drugs Historic Market Size by Application (2020-2025)
4.2 Global siRNA Drugs Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in siRNA Drugs Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top siRNA Drugs Players by Revenue (2020-2025)
5.1.2 Global siRNA Drugs Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by siRNA Drugs Revenue
5.4 Global siRNA Drugs Market Concentration Analysis
5.4.1 Global siRNA Drugs Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by siRNA Drugs Revenue in 2024
5.5 Global Key Players of siRNA Drugs Head office and Area Served
5.6 Global Key Players of siRNA Drugs, Product and Application
5.7 Global Key Players of siRNA Drugs, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America siRNA Drugs Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America siRNA Drugs Market Size by Type (2020-2025)
6.1.2.2 North America siRNA Drugs Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America siRNA Drugs Market Size by Application (2020-2025)
6.1.3.2 North America siRNA Drugs Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe siRNA Drugs Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe siRNA Drugs Market Size by Type (2020-2025)
6.2.2.2 Europe siRNA Drugs Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe siRNA Drugs Market Size by Application (2020-2025)
6.2.3.2 Europe siRNA Drugs Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific siRNA Drugs Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific siRNA Drugs Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific siRNA Drugs Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific siRNA Drugs Market Size by Application (2020-2025)
6.3.3.2 Asia-Pacific siRNA Drugs Market Share by Application (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America siRNA Drugs Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America siRNA Drugs Market Size by Type (2020-2025)
6.4.2.2 Latin America siRNA Drugs Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America siRNA Drugs Market Size by Application (2020-2025)
6.4.3.2 Latin America siRNA Drugs Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa siRNA Drugs Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa siRNA Drugs Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa siRNA Drugs Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa siRNA Drugs Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa siRNA Drugs Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Alnylam
7.1.1 Alnylam Company Details
7.1.2 Alnylam Business Overview
7.1.3 Alnylam siRNA Drugs Introduction
7.1.4 Alnylam Revenue in siRNA Drugs Business (2020-2025)
7.1.5 Alnylam Recent Development
7.2 Novartis
7.2.1 Novartis Company Details
7.2.2 Novartis Business Overview
7.2.3 Novartis siRNA Drugs Introduction
7.2.4 Novartis Revenue in siRNA Drugs Business (2020-2025)
7.2.5 Novartis Recent Development
7.3 Novo Nordisk
7.3.1 Novo Nordisk Company Details
7.3.2 Novo Nordisk Business Overview
7.3.3 Novo Nordisk siRNA Drugs Introduction
7.3.4 Novo Nordisk Revenue in siRNA Drugs Business (2020-2025)
7.3.5 Novo Nordisk Recent Development
7.4 Genzyme
7.4.1 Genzyme Company Details
7.4.2 Genzyme Business Overview
7.4.3 Genzyme siRNA Drugs Introduction
7.4.4 Genzyme Revenue in siRNA Drugs Business (2020-2025)
7.4.5 Genzyme Recent Development
7.5 Arrowhead
7.5.1 Arrowhead Company Details
7.5.2 Arrowhead Business Overview
7.5.3 Arrowhead siRNA Drugs Introduction
7.5.4 Arrowhead Revenue in siRNA Drugs Business (2020-2025)
7.5.5 Arrowhead Recent Development
7.6 Silence
7.6.1 Silence Company Details
7.6.2 Silence Business Overview
7.6.3 Silence siRNA Drugs Introduction
7.6.4 Silence Revenue in siRNA Drugs Business (2020-2025)
7.6.5 Silence Recent Development
7.7 Sylentis
7.7.1 Sylentis Company Details
7.7.2 Sylentis Business Overview
7.7.3 Sylentis siRNA Drugs Introduction
7.7.4 Sylentis Revenue in siRNA Drugs Business (2020-2025)
7.7.5 Sylentis Recent Development
7.8 Avidity Biosciences
7.8.1 Avidity Biosciences Company Details
7.8.2 Avidity Biosciences Business Overview
7.8.3 Avidity Biosciences siRNA Drugs Introduction
7.8.4 Avidity Biosciences Revenue in siRNA Drugs Business (2020-2025)
7.8.5 Avidity Biosciences Recent Development
7.9 Sirnaomics
7.9.1 Sirnaomics Company Details
7.9.2 Sirnaomics Business Overview
7.9.3 Sirnaomics siRNA Drugs Introduction
7.9.4 Sirnaomics Revenue in siRNA Drugs Business (2020-2025)
7.9.5 Sirnaomics Recent Development
8 siRNA Drugs Market Dynamics
8.1 siRNA Drugs Industry Trends
8.2 siRNA Drugs Market Drivers
8.3 siRNA Drugs Market Challenges
8.4 siRNA Drugs Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Global siRNA Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global siRNA Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market siRNA Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global siRNA Drugs Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global siRNA Drugs Revenue Share by Region (2020-2025)
Table 6. Global siRNA Drugs Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global siRNA Drugs Revenue Share Forecast by Region (2026-2031)
Table 8. Global siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global siRNA Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global siRNA Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global siRNA Drugs Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global siRNA Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global siRNA Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global siRNA Drugs Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in siRNA Drugs Application
Table 18. Global siRNA Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global siRNA Drugs Market Share by Players (2020-2025)
Table 20. Global Top siRNA Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)
Table 21. Ranking of Global Top siRNA Drugs Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by siRNA Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of siRNA Drugs, Headquarters and Area Served
Table 24. Global Key Players of siRNA Drugs, Product and Application
Table 25. Global Key Players of siRNA Drugs, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America siRNA Drugs Revenue Market Share by Company (2020-2025)
Table 29. North America siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe siRNA Drugs Revenue Market Share by Company (2020-2025)
Table 33. Europe siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 35. Asia-Pacific siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 36. Asia-Pacific siRNA Drugs Revenue Market Share by Company (2020-2025)
Table 37. Asia-Pacific siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 38. Asia-Pacific siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 39. Latin America siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 40. Latin America siRNA Drugs Revenue Market Share by Company (2020-2025)
Table 41. Latin America siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 42. Latin America siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 43. Middle East & Africa siRNA Drugs Revenue by Company (2020-2025) & (US$ Million)
Table 44. Middle East & Africa siRNA Drugs Revenue Market Share by Company (2020-2025)
Table 45. Middle East & Africa siRNA Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 46. Middle East & Africa siRNA Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 47. Alnylam Company Details
Table 48. Alnylam Business Overview
Table 49. Alnylam siRNA Drugs Product
Table 50. Alnylam Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 51. Alnylam Recent Development
Table 52. Novartis Company Details
Table 53. Novartis Business Overview
Table 54. Novartis siRNA Drugs Product
Table 55. Novartis Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Novo Nordisk Company Details
Table 58. Novo Nordisk Business Overview
Table 59. Novo Nordisk siRNA Drugs Product
Table 60. Novo Nordisk Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 61. Novo Nordisk Recent Development
Table 62. Genzyme Company Details
Table 63. Genzyme Business Overview
Table 64. Genzyme siRNA Drugs Product
Table 65. Genzyme Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 66. Genzyme Recent Development
Table 67. Arrowhead Company Details
Table 68. Arrowhead Business Overview
Table 69. Arrowhead siRNA Drugs Product
Table 70. Arrowhead Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 71. Arrowhead Recent Development
Table 72. Silence Company Details
Table 73. Silence Business Overview
Table 74. Silence siRNA Drugs Product
Table 75. Silence Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 76. Silence Recent Development
Table 77. Sylentis Company Details
Table 78. Sylentis Business Overview
Table 79. Sylentis siRNA Drugs Product
Table 80. Sylentis Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 81. Sylentis Recent Development
Table 82. Avidity Biosciences Company Details
Table 83. Avidity Biosciences Business Overview
Table 84. Avidity Biosciences siRNA Drugs Product
Table 85. Avidity Biosciences Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 86. Avidity Biosciences Recent Development
Table 87. Sirnaomics Company Details
Table 88. Sirnaomics Business Overview
Table 89. Sirnaomics siRNA Drugs Product
Table 90. Sirnaomics Revenue in siRNA Drugs Business (2020-2025) & (US$ Million)
Table 91. Sirnaomics Recent Development
Table 92. siRNA Drugs Market Trends
Table 93. siRNA Drugs Market Drivers
Table 94. siRNA Drugs Market Challenges
Table 95. siRNA Drugs Market Restraints
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. siRNA Drugs Product Picture
Figure 2. Global siRNA Drugs Market Share by Type: 2024 VS 2031
Figure 3. Intravenous Injection Features
Figure 4. Subcutaneous Injection Features
Figure 5. Global siRNA Drugs Market Share by Application: 2024 VS 2031
Figure 6. Nervous System Therapy
Figure 7. Endocrine and Metabolic Therapy
Figure 8. Others
Figure 9. siRNA Drugs Report Years Considered
Figure 10. Global siRNA Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 11. Global siRNA Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global siRNA Drugs Revenue Market Share by Region: 2020 VS 2024
Figure 13. North America siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Europe siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Asia-Pacific siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Latin America siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Middle East & Africa siRNA Drugs Revenue (US$ Million) Growth Rate (2020-2031)
Figure 18. Global siRNA Drugs Market Share by Players in 2024
Figure 19. Global Top siRNA Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in siRNA Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by siRNA Drugs Revenue in 2024
Figure 21. North America siRNA Drugs Market Share by Type (2020-2025)
Figure 22. North America siRNA Drugs Market Share by Application (2020-2025)
Figure 23. Europe siRNA Drugs Market Share by Type (2020-2025)
Figure 24. Europe siRNA Drugs Market Share by Application (2020-2025)
Figure 25. Asia-Pacific siRNA Drugs Market Share by Type (2020-2025)
Figure 26. Asia-Pacific siRNA Drugs Market Share by Application (2020-2025)
Figure 27. Latin America siRNA Drugs Market Share by Type (2020-2025)
Figure 28. Latin America siRNA Drugs Market Share by Application (2020-2025)
Figure 29. Middle East & Africa siRNA Drugs Market Share by Type (2020-2025)
Figure 30. Middle East & Africa siRNA Drugs Market Share by Application (2020-2025)
Figure 31. Alnylam Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 32. Novartis Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 33. Novo Nordisk Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 34. Genzyme Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 35. Arrowhead Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 36. Silence Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 37. Sylentis Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 38. Avidity Biosciences Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 39. Sirnaomics Revenue Growth Rate in siRNA Drugs Business (2020-2025)
Figure 40. Bottom-up and Top-down Approaches for This Report
Figure 41. Data Triangulation
Figure 42. Key Executives Interviewed
